



Charles River Laboratories Announces Strategic Partnership with Kibur Medical to Advance Preclinical Oncology Studies

February 25, 2021 at 8:00 AM EST

Implantable microdevice provides unique insight into individual and combination therapy efficacy during early-stage discovery

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 25, 2021-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for *in vivo* preclinical oncology studies.

Kibur's Unique Technology

The IMD provides an opportunity to transform how researchers may assess efficacy of oncology compounds *in vivo* as both individual and combination therapies. Kibur's microdevice technology can hold up to 20 different compounds for local administration, which allow it to:

- Measure interactions between disease tissue and microdoses of therapies to predict the optimal drug regimen;
- Rapidly test multiple combinations at once *in vivo* in most solid tumors;
- Dose therapies directly into disease tissue, allowing for investigative studies of early-stage compounds where pharmacokinetic properties are poorly understood.

Data-Driven Decisions

According to a study in [Biostatistics](#), oncology drugs have a 97% failure rate in clinical trials. Together with Charles River's leading expertise in [early-stage preclinical testing](#), researchers can utilize the Kibur technology to perform *in vivo* testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models. Additionally, Kibur's IMD provides both a platform to observe synergies of drug combinations and a time and cost-sensitive testing solution for extending indications of existing oncology drugs.

Excised tumor tissue is analyzed via multiplex immuno-histochemistry, immune cell readouts, spatial transcriptomics and MALDI-TOF mass spectrometry providing for rich datasets in short cycle times and thereby improved decision making early in the preclinical process.

Approved Quotes

- "We are proud to partner with Kibur Medical to help advance our oncology service offering. The development of cancer therapies is extremely nuanced, and Kibur's technology provides clients with important data on drug efficacy to help inform their preclinical programs." –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River
- "When looking for a strategic partner, we knew we wanted an organization with global reach and a strong scientific bench. Charles River's longstanding reputation as an industry leader will help deliver our technology to the widest possible network, providing a huge opportunity to help develop the next generation of cancer therapeutics." – Oliver Jonas, PhD, Scientific Founder, Kibur Medical

About Kibur Medical

Kibur Medical is a clinical stage biomedical company that develops devices and microsensors for *in vivo* applications. The company focuses on applications of its technology to develop precision treatments for cancer and other diseases, as well as enabling more efficient drug development in the preclinical and clinical space.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20210225005083/en/>

Investors:

Todd Spencer
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com

Media:

Amy Cianciaruso
Corporate Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com

Source: Charles River Laboratories International, Inc.